• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Treating Bipolar 1 Disorder

By: 3BL Media
May 24, 2022 at 05:00 AM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Healthcare professionals share perspectives on providing care for people living with bipolar 1 disorder

SOURCE: Alkermes

DESCRIPTION:

Check out a new infographic with findings from our latest survey conducted in partnership with The Harris Poll and Depression and Bipolar Support Alliance – National Headquarters. Learn what healthcare providers (HCPs) had to say about treating individuals with bipolar 1 disorder: https://bit.ly/383gMvq

About Alkermes
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Tweet me: .@Alkermes has created a new infographic from findings with @HarrisPoll and @DBSAlliance on what healthcare providers (HCPs) had to say about treating individuals with #bipolar 1 disorder: https://bit.ly/3FPKj8a

KEYWORDS: NASDAQ: ALKS, Alkermes

Text: Treating Bipolar 1 Disorder, Healthcare Professionals Share Perspectives on Providing Care for People Living with Bipolar 1 Disorder

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More
News headline image
GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care ↗
Today 18:02 EDT
Via MarketBeat
Topics Artificial Intelligence Intellectual Property
Tickers GSK
News headline image
Okta Sees AI Agent Identity Market Outgrowing Traditional IAM at Oktane 2026 ↗
Today 17:02 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers OKTA
News headline image
Gevo Sees Carbon Credits, 45Z Incentives Driving $60M EBITDA Outlook ↗
Today 16:02 EDT
Via MarketBeat
Topics Energy
Tickers ASX:TWR GEVO
News headline image
Chips to Bots: Qualcomm’s Agentic AI Breakout ↗
Today 15:05 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers AAPL GLW LITE QCOM
News headline image
Okta Unveils AI Agent Security Blueprint Alliance at Oktane ↗
Today 15:02 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers AMZN CRWD OKTA

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.27
-5.71 (-2.24%)
AAPL  337.02
-2.73 (-0.80%)
AMD  614.61
-9.16 (-1.47%)
BAC  56.00
-0.20 (-0.36%)
GOOG  334.98
-12.43 (-3.58%)
META  744.10
+7.51 (1.02%)
MSFT  500.59
+2.59 (0.52%)
NVDA  225.51
-3.36 (-1.47%)
ORCL  144.56
-4.64 (-3.11%)
TSLA  380.12
+1.22 (0.32%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap